Global S&T Development Trend Analysis Platform of Resources and Environment
DOI | 10.1038/s41467-018-03383-w |
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer | |
Liu, Yunhua1,2,3; Xu, Jiangsheng4,5,6; Choi, Hyun Ho2; Han, Cecil2; Fang, Yuanzhang1,2; Li, Yujing1,2; Van der Jeught, Kevin1,2; Xu, Hanchen1,2; Zhang, Lu1,2,3; Frieden, Michael1; Wang, Lifei1; Eyvani, Haniyeh1; Sun, Yifan1; Zhao, Gang7; Zhang, Yuntian4,5,6; Liu, Sheng1; Wan, Jun1; Huang, Cheng8; Ji, Guang3; Lu, Xiongbin1,2,9; He, Xiaoming4,5,6,10,11; Zhang, Xinna1,9,12,13 | |
2018-11-09 | |
发表期刊 | NATURE COMMUNICATIONS |
ISSN | 2041-1723 |
出版年 | 2018 |
卷号 | 9 |
文章类型 | Article |
语种 | 英语 |
国家 | USA; Peoples R China |
英文摘要 | Chromosome 17q23 amplification occurs in similar to 11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majority of the WIP1-containing 17q23 amplicons. The 17q23 amplification results in aberrant expression of WIP1 and miR-21, which not only promotes breast tumorigenesis, but also leads to resistance to anti-HER2 therapies. Inhibiting WIP1 and miR-21 selectively inhibits the proliferation, survival and tumorigenic potential of the HER2+ breast cancer cells harboring 17q23 amplification. To overcome the resistance of trastuzumab-based therapies in vivo, we develop pH-sensitive nanoparticles for specific co-delivery of the WIP1 and miR-21 inhibitors into HER2+ breast tumors, leading to a profound reduction of tumor growth. These results demonstrate the great potential of the combined treatment of WIP1 and miR-21 inhibitors for the trastuzumab-resistant HER2+ breast cancers. |
领域 | 资源环境 |
收录类别 | SCI-E |
WOS记录号 | WOS:000449627800013 |
WOS关键词 | DNA-DAMAGE RESPONSE ; COMPREHENSIVE MOLECULAR PORTRAITS ; METASTATIC BREAST-CANCER ; WIP1 PHOSPHATASE ; TUMOR-SUPPRESSOR ; TRASTUZUMAB RESISTANCE ; EXPRESSION ; RNA ; PPM1D ; GENE |
WOS类目 | Multidisciplinary Sciences |
WOS研究方向 | Science & Technology - Other Topics |
URL | 查看原文 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/203693 |
专题 | 资源环境科学 |
作者单位 | 1.Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; 2.Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; 3.Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai 200032, Peoples R China; 4.Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA; 5.Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; 6.Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA; 7.Univ Sci & Technol China, Sch Informat Sci & Technol, Dept Elect Sci & Technol, Hefei 230027, Anhui, Peoples R China; 8.Shanghai Univ Tradit Chinese Med, Sch Pharm, Drug Discovery Lab, Shanghai 201203, Peoples R China; 9.Indiana Univ Sch Med, Indiana Univ Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; 10.Univ Maryland, Robert E Fischell Inst Biomed Devices, College Pk, MD 20742 USA; 11.Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; 12.Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Non Coding RNAs, Houston, TX 77030 USA; 13.Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA |
推荐引用方式 GB/T 7714 | Liu, Yunhua,Xu, Jiangsheng,Choi, Hyun Ho,et al. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer[J]. NATURE COMMUNICATIONS,2018,9. |
APA | Liu, Yunhua.,Xu, Jiangsheng.,Choi, Hyun Ho.,Han, Cecil.,Fang, Yuanzhang.,...&Zhang, Xinna.(2018).Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer.NATURE COMMUNICATIONS,9. |
MLA | Liu, Yunhua,et al."Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer".NATURE COMMUNICATIONS 9(2018). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论